Good MorningEquity markets started Tuesday's session on an uncertain footing after tensions in Ukraine escalated. However, the market quickly regained footing to confirm support at a critical level, aligning with the election-inspired rally two weeks ago. With this in play, the odds are high that the election-driven rally is not over and that the S&P 500 index will soon set a new high.
Results from Walmart aided the market rebound. The world's largest employer outpaced consensus on the top and bottom lines and raised its guidance, citing resilient consumer health and steady spending. The news suggests the holiday shopping season will be merry and bright, lifting Walmart's stock price by 5% to set a new all-time high. Analysts are lifting their targets for WMT stock, which may continue to trend higher through the end of the year. Featured: Solar lost. Wind lost. One won. (Ad) 
|
Energy | |
The ultimate goal of a business is to generate cash for its shareholders. Investors often consider net income the “bottom line” of a business, indicating how much profit it makes. Net income equals revenue minus expenses. However, some types of revenue and some types of expenses don&rs... Read the Full Story |
|
From Our Partners | | Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | |
|
Technology | | In an industry often characterized by high growth rather than dividend income, finding semiconductor companies that offer both can be particularly appealing. Below are three semiconductor stocks that provide investors with dividend payouts and have recently announced notable increases. I’ll re... Read the Full Story |
|
Retail/Wholesale | |
While Target (NYSE: TGT) has been a bellwether of retail sector health in recent years, it is not today. The company’s lackluster results are due to its operational quality and lack of relevance in an environment where consumers are budget-conscious. Results from other retailers, including... Read the Full Story |
|
From Our Partners | | A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big Tech and Washington policymakers. It can be trucked to a data center, military base, or industrial site and deliver reliable power for years without grid access.
A key government milestone expected this August could bring significant visibility to this space. One small stock sits at the center of it. | | Read the full breakdown and see which stock to watch now |
|
Retail/Wholesale | |
Williams-Sonoma (NYSE: WSM) offers everything an investor could want and more, making it a stock worthy of buy-and-hold status. Its quality is centered on the brand and operations, which CEO Laura Alber stewards. The results of her tenure include growth, operational improvement, market share gain,... Read the Full Story |
|
Markets | |
For conservative investors seeking steady income and long-term growth, dividend ETFs offer a reliable "buy and hold" strategy. These funds provide diversification, consistent payouts, and the ease of passive management, making them ideal for a stable, hands-off portfolio. With careful selection, d... Read the Full Story |
|
From Our Partners | | Wall Street spends millions on supercomputers and analyst teams to forecast stock prices. Now a new predictive AI is giving Main Street investors access to the same edge - forecasting over 2,334 stocks up to 21 days into the future.
Built on a principle similar to hurricane tracking models, this AI has unlocked an investing approach that reportedly beats buy-and-hold five to one. You don't need to be a hedge fund or a millionaire to use it. | | Watch the free Predictive AI demo and get five stock picks today |
|
Consumer Discretionary | |
Warren Buffett recently made news about the stocks that Berkshire Hathaway Inc. (NYSE: BRK.B) sold. But it looks like Buffett isn’t sitting this rally out completely. On November 15, Buffett made two significant purchases in two stocks that the company had not previously owned. The stocks we... Read the Full Story |
|
Technology | |
Impinj (NASDAQ: PI) is a mid-cap chip stock that has quietly had a great year in 2024. The stock has returned over 93%, placing it among the top five best returning semiconductor stocks in the United States. Wall Street analysts remain bullish on the stock. The average of the seven price targets... Read the Full Story |
|
Technology | |
Advertising technology (adtech) giant The Trade Desk Inc. (NASDAQ: TTD) is the leading independent demand-side platform (DSP) for programmatic advertising. The company’s artificial intelligence (AI) powered adtech platform, Kokai, enables brands and marketers to specify and target the exact ... Read the Full Story |
|
Consumer Discretionary | |
The pandemic triggered a boom in stocks that accommodated physical isolation, convenient access from home, and fitness. Many of these stocks hit unbelievable highs during the lockdowns but collapsed just as hard in the post-pandemic normalization period afterward. While many of these stocks faded ... Read the Full Story |
|
Retail/Wholesale | |
Dutch Bros Inc. (NYSE: BROS) is a thriving drive-thru coffee shop operator and franchisor operating 950 shops across 18 states. While primarily focused on coffee drinks, they also offer teas, smoothies, protein and energy drinks. They prioritize speed and efficiency with an app-driven, drive-thru-... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. | | View Today's Stock Pick |
|
